From lifesaving Hepatitis C medicines that only a fraction of people in need can afford, to overnight price hikes on decades-old medicines, to growing resistance to existing antibiotic treatments, the rising price of medicines and lack of patient-focused research and development is a crisis that can no longer be ignored.
In our field programs every day, Doctors Without Borders/Médecins Sans Frontières (MSF) not only grapples with the high price of medicines and vaccines, but also with a lack of research and development for neglected patients.
But it doesn’t have to be this way. In a special October 26 webcast, a panel of international and US experts took a deeper look at the causes and consequences of high-priced medicines globally, and opportunities to improve a system that is failing patients who urgently need access to effective and affordable innovation.
Dr. Manica Balasegaram, Executive Director, MSF Access Campaign
Judit Rius Sanjuan, US Manager and Legal Policy Advisor, MSF Access Campaign
Tracy Swan, Hepatitis/HIV Project Director, Treatment Action Group
Moderated by Sandra Murillo, Media Relations Manager, Doctors Without Borders
Viewer participation is encouraged via a chat feature available during the webcast.